P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
Ronald van Vollenhoven(Amsterdam University Medical Centers), Eric F. Morand(Novartis (Switzerland)), Joseph F. Merola(Southwestern Medical Center), Coburn Hobar(Bristol-Myers Squibb (United States)), Ravi Koti(Syneos Health (United States)), Piotr Leszczyński(Poznan University of Medical Sciences), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Marilyn C. Pike(Bethesda Hospital), Samantha Pomponi(Bristol-Myers Squibb (United States)), Matthew J. Colombo(Bristol-Myers Squibb (United States)), Kathryn H. Dao(The University of Texas Southwestern Medical Center), Thomas Wegman(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728